Concord Biotech Ltd (CONCORDBIO) Q1 FY27 Earnings Call: API Exports Surge 46%, Margin Trajectory Toward 40%

Concord Biotech Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Revenue Growth with Margin Expansion

• Q1 FY27 revenue of Rs.257 Cr — up 26.2% YoY from Rs.204 Cr in Q1 FY26, driven by broad-based growth across immunosuppressants, anti-infectives, oncology, and anti-fungals.
• API segment revenue grew 42% to Rs.219 Cr — formulation revenue declined 23% to Rs.39 Cr, though management cautions that overall business growth, not segment mix, is the key metric.
• Export revenue grew 46% YoY — domestic revenue grew 12% in Q1 FY27, supported by increasing inquiries from regulated and semi-regulated markets.
• Gross margin improved 100 bps YoY to 78.9% — driven by pricing discipline and favorable product mix in Q1 FY27.
• EBITDA of Rs.82 Cr (up 34% YoY), margin 32% — up 190 bps YoY. Excluding inducted facilities and Stellon Biotech expenses, EBITDA margin would have been 37%.
• PAT of Rs.58 Cr (up 31% YoY), margin 22.4% — up 80 bps YoY in Q1 FY27.
• Zero-debt balance sheet with Rs.442 Cr cash — as of 30 Jun 2026; Q1 FY27 capex was Rs.9.5 Cr.

API Exports Surge 46%; Long-Term Roadmap Targets Rs.2,200 Cr

• API exports grew ~46% in Q1 FY27 — partly reflecting spillover from delayed Q4 FY26 customer procurement, but management attributed most growth to new products and geographic expansion (US, Europe, Japan, LatAm).
• Management expects similar spillover benefits in subsequent quarters of FY27 — and is on track to deliver growth better than historical rates.
• Management targets API revenue of Rs.2,200 Cr over the next 5-6 years — stating that "existing manufacturing infrastructure can support ~Rs.3,000 crores in revenue over a 5-6 year horizon," comprising Rs.600-700 Cr from formulations and Rs.2,200 Cr from APIs.
• Revenue growth expected from product mix shift to higher-value oncology products — using the 5,000-liter fermenter, and new anti-infective/anti-fungal launches, even if overall capacity utilization increases only marginally.
• Management has 8-10 pipeline products — of which 2-3 are oncology and the rest are anti-infectives/anti-fungals, all to be added to Unit 3.
• Fusidic acid, launched in FY26, is expected to contribute meaningfully in FY27 and FY28 — Nystatin is already performing well; Fusidic acid is a niche large-volume product with limited competition, pending CEP approval for Europe.

Three Nascent Verticals — CDMO, Injectables, and Stellon — Poised for Scale

• Management views all three segments (CDMO, injectables, Stellon) as equally important — all at a nascent stage; no single priority is singled out.
• Injectable facility has capacity to generate ~Rs.600 Cr in revenue — positioned as India's only fully integrated fermentation API-to-finished product plant with WHO GMP certification, completed validation batches, and ongoing customer audits.
• Injectable plant utilization was ~5% in Q1 FY27 — emerging market approvals expected in 12-15 months, with sales anticipated to start in FY27-28. Near-term focus on maximizing domestic utilization via branded generics and contract manufacturing, with commercialization expected in H2 FY27.
• Stellon Biotech (US front-end formulation platform) commenced commercial operations in Q1 FY27 — currently nascent but seen as a potential meaningful contributor in coming years; expects to benefit from ANDA approvals and in-licensing third-party products.
• CDMO: one project (animal health, US market) is commercialized — generating a couple of million dollars in sales in Q1 FY27; management expects slow, steady market share gains. At least one additional project expected to commercialize in FY27.
• CDMO currently contributes 1-2% of sales — management intends to make it a double-digit contributor.

Margin Trajectory Toward 40%; Zero-Debt Balance Sheet

• EBITDA margin improved 190 bps YoY to 32% in Q1 FY27 — excluding inducted facilities and Stellon expenses, the margin would have been 37%.
• Management expects to move toward 40% EBITDA margin in FY27-28 — as the injectable facility and Stellon business ramp up; operating leverage and renewable energy support improvement. Analyst Alok Dalal concluded the 40% target is more likely in FY27-28; management confirmed.
• Constant currency revenue growth for Q1 FY27 was ~10% YoY — above the historical 3-4% rate; net forex and input cost impact on EBITDA is estimated at up to 5%.
• Gross margin improved 100 bps YoY to 78.9% in Q1 FY27 — driven by pricing discipline and favorable product mix.
• Wallet share gains in Q1 FY27 were driven by pricing advantage from 1,250 m³ fermentation capacity — primarily on existing products; new product contributions (Nystatin, Fusidic acid) are expected in coming quarters.
• Company is zero-debt with Rs.442 Cr in cash and equivalents — Q1 FY27 capex was Rs.9.5 Cr. Capital allocation priorities include dividends, organic growth, and inorganic growth in fermentation adjacencies.

Ample Brownfield Headroom Across Units 1-3

• Q1 FY27 capacity utilization: Unit 1 at 80%, Unit 2 at 45%, Unit 3 at 55% — Unit 3 utilization excluding KSMs is slightly higher than 20-25% per management's estimate.
• Management targets Rs.2,200-2,300 Cr API sales over the next 5-6 years on current capacity — capex for additional API capacity will be considered when utilization reaches 80-85% at Unit 3.
• Only 20-25% of the 160 acres at Unit 3 is currently utilized — providing substantial brownfield expansion space.
• Dedicated fermentation capacities for adjacencies (peptides, veterinary products) may be added before the 80-85% utilization threshold — indicating flexibility in capital allocation.
• Formulation (injectable) capacity alone can generate ~Rs.600 Cr in revenue — with current utilization at ~5% in Q1 FY27, offering significant headroom for growth.
• All segments grew double-digits in value terms in Q1 FY27 — anti-infectives and oncology saw higher percentage growth than immunosuppressants; Nystatin and other products cited as driving traction.

Robust Pipeline, Regulatory Milestones, and Sustained Momentum

• Management expressed confidence in sustaining momentum through the rest of FY27 — citing business visibility and a robust pipeline.
• Regulatory milestones in Q1 FY27 — inspections completed by Anvisa Brazil (Limbasi facility) and PPB Kenya/NDA Uganda (Unit 2 formulation at Valthera); ANDA approvals received from USFDA for mycophenolate mofetil suspension and tofacitinib tablets.
• Company plans to launch 2-3 new products annually — several products at advanced development stage with commercialization expected in the coming quarters of FY27.
• Management added two innovator customers in FY26 — and expects a couple more projects to reach advanced stages or closure by end of FY27.
• On tariffs, management has not heard any concerns from customers — regarding the 100% tariff on generics proposed two years out.
• Prior headwinds (FY26): customer buying pattern shifts, CDSCO approval delays, and tariff uncertainties — management believes these are navigable and not new to the company.
• EcoVadis awarded Concord a silver medal — placing it in the top 15% of assessed companies globally.